TransGenex Nanobiotech, Inc.

TransGenex Nanobiotech Inc. (TGN), is a Florida-based nanobiotechnology company incorporated in 2004.

Our Mission is to discover, develop and commercialize nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.

Contact Us

%

Drugs make it to the clinic after discovery using 2D cell culture

%

Adoption of 3D cell culture platform for cancer drug discovery

%

Global cancer drug market growth

%

Global deaths caused by cancer

What We Offer

At Transgenex, we make innovative technological platforms for researchers and clinicians to use in their translational and basic science research. Presently, the company has developed and optimized a simple 3D cell culture platform for oncology research. The company also offers services including customized nanoparticle-mediated delivery systems to fit the client’s needs and drug-screening services utilizing our 3D platform.

Our Mission is to discover, develop and commercialize nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.

At Transgenex, we believe that every employee has a role in contributing to the success of the company. Therefore, we encourage employees to proactively design projects, share ideas and take active part in the decision making process.



FiSS 96-well 3D Tumoroid forming plates

Slide1

Find Out More

FiSS 96-well 3D Tumoroid forming plates

Grow 3D Cell Culture

The patented FiSSTM 96-well plates allows for growing three-dimensional (3D) cell culture without the requirements for additional device or customized growth media.

Versatility

The plates are very versatile and protocols can be modified easily to accommodate the requirements of your research needs.

Testing

The plates have been tested for drug screening, flow cytometry studies, fluorescence and confocal microscopy studies, reporter assays, peoteomics and gene expression analysis.

FiSS 3D Tumoroid forming disks

Grow 3D Cell Culture

The patented FiSSTM disks allows for growing three-dimensional (3D) cell culture without the requirements for additional device or customized growth media.

Versatility

The disks are designed to fit into a standard 96 well plate and thus gives tremendous flexibility to researchers with their study design.

Testing

Similar to the FiSSTM 3D Tumoroid forming plates, the disks have been tested for drug screening, flow cytometry studies, fluorescence and confocal microscopy studies, reporter assays, peoteomics and gene expression analysis.

FiSS 3D Tumoroid forming disks

Slide2

Find Out More

TransGenex Promotional Video

Frequently Asked Questions

FiSS™

This is a pioneering fiber-inspired smart scaffold technology platform that enables development of multicellular tumor spheroids (MTS) that fully resemble tumors in vivo. The MTS is expected to aid in anti-cancer drug discovery and development and in predicting the clinical efficacy of drugs for personalized cancer treatment.

The advantages of FiSS include:

• Rapid (2-3 days) development of tumor spheroids
• Tumoroids grow >500 µm in diameter
• Tumoroids can be cultured up to 20 days
• FiSS does not require trypsin to dislodge tumors
• Spheroids do not arise from single cells
• Tumoroids exhibit multicellular interactions
• FiSS is an ideal screening platform for anti-cancer drug discovery and development

 

Do you need special cell culture plates to grow 3D cell culture using FiSS platform?

No, the FiSS discs can be used in all the 96-, 24-, 12- and 6- well cell culture plates and the FiSS tumoroids micro-plate is provided in a standard 96-well cell culture plate format.

What cells can be grown on the FiSS platform?

We have tested growing; (i) cancer cell lines, (ii) co-culture of cancer cell lines with fibroblasts, mesenchymal stem cells or immune cells (Macrophages, T cells) (iii) tumor tissue from patient and tumor biopsies from in vivo mouse studies.

Are there any scientific studies that have been published using the FiSS platform?

Yes, there is a study published in PLoS One that characterizes our FiSS platform (http://www.ncbi.nlm.nih.gov/pubmed/24146752).


While traditional cancer research applies new treatments to cancer cells, this product would allow researchers to directly apply them to tumors.

The Oracle describing TGN’s 3D cell culture platform

TransGenex’s product, Tumor-on-a-Dish, promises to help drug discovery through a 3D model. The 2D models typically used are less accurate for predicting patient response to drugs, according to the statement.

The Tampa Bay Business Journal

To its existing platforms, such as ULTraPID™ for diagnosis and TARGETTM for nanopharmaceutics, this year TGN has added a three-dimensional multi-cell tumor (‘Tumor- on- a-dish’) platform, which aims to facilitate cancer drug discovery, drug development and personalized cancer treatment.

University of South Florida Research and Innovation News